Director, Open Targets
Ian Dunham is Director of Open Targets, an innovative public-private partnership to improve identification and prioritisation of drug targets. Open Targets conducts research programmes in bioinformatics and experimental genomics and genetics to integrate data that will improve drug target choice.
As part of the partnership, Ian's group have developed the Open Targets Platform and the Open Targets Genetics Portal to provide public access to integrated information around the likely efficacy of a drug target. These resources interact with a number of other groups within EMBL-EBI including the SPOT team for ontologies, GWAS catalog, Chembl, EVA, Uniprot, EuropePMC and Expression Atlas.
Ian's earlier research interests include experimental and computational approaches to genome-wide mapping of regulatory elements and chromatin state in the human genome as part of the NHGRI ENCODE project, as well as understanding the influence of variation on regulatory elements in human and other organisms, including leading the Ensembl Regulation team.
He was previously a Senior Group Leader at the Wellcome Sanger Institute from 1993, focusing first on genome sequencing including the first human chromosome sequence in 1999, and subsequently on developing functional maps of the human genome. This included gene structure maps, variation maps, and the first chromosome-wide linkage disequilibrium map. He also holds an Associate Faculty postion at the Wellcome Sanger Institute.
dunham [at] ebi.ac.uk
ORCID iD: 0000-0003-2525-5598
Tel:+ 44 (0) 1223 492 636 / Fax:
Open Targets aims to provide evidence on the biological validity of therapeutic targets and provide an initial assessment of the likely effectiveness of pharmacological intervention on these targets, using genome-scale experiments and analysis. Open Targets aims to provide an R&D framework that applies to all aspects of human disease, and to share its data openly with the scientific community.
The goal of Open Targets is to provide an R&D framework that applies to all aspects of human disease, and to share its data openly with the scientific community. It is a shared initiative between the European Bioinformatics Institute (EMBL-EBI), a global leader in the management, integration and analysis of public domain life science data; GSK, a leading, global pharmaceutical company; Biogen, one of the world’s oldest independent biotechnology companies; Takeda, a global, research and development-driven pharmaceutical company and the Wellcome Sanger Institute, a world-leading genomics institution with expertise in human genetics, cancer and infectious disease. Open Targets exists as a core operation within the Innovation Centre of EMBL-EBI's South Building on the Wellcome Genome Campus and involves staff from each of the institutions directly interacting there with access to the full normal scientific life of the campus. In addition it draws upon expertise from groups within the institutions spreading connections across the sites.